Company Profile

New Horizon Longevity Technology Co., Limited occupies a high ground in eye health research and clinical practice, laying out technological innovation in the entire diagnosis and treatment chain.
The product includes Herbal Brightening and Aging Eye Care Liquid, Macular Eye Care Liquid, Eye Moisturizing Spray, etc. Laohua Eye Protection Liquid, a traditional Chinese medicine product under the name of Materia Medica, is the second monomeric product under modern medical technology after artemisinin; Macular eye care solution can alleviate visual impairment caused by macular degeneration; Moisturizing eye spray can prevent eye diseases and relieve visual fatigue.
The drug pipeline has global innovation. The breakthrough drug R&D pipeline includes the herbal Mingmu Laohua Eye Care Liquid 2.0 pipeline, which will benefit patients with diabetes retinopathy or presbyopia, age-related macular degeneration, cataract and glaucoma; The company cooperates with the Hong Kong government and Professor Zhou of the Hong Kong Polytechnic University to develop eye drops and oral supplements to treat diabetes retinopathy and presbyopia; Cooperate with the Hong Kong government and Dean Feng of the School of Traditional Chinese Medicine of the University of Hong Kong to develop drug pipelines for diabetes retinopathy and macular diseases.
Introduction to longevity drugs: NAD+products synthesized from traditional Chinese medicine are undergoing clinical research with the School of Chinese Medicine at the University of Hong Kong.
Some of the company's pipelines have entered the stage of full industrialization and plan to go public in the United States in 2025. After going public, we will use capital market financing to promote the third phase clinical and industrialization of other pipelines

Development History

  • Establishment of Hong Kong Group Company
    Research on investment in the medical industry, preparing for the introduction of high-end medical technology;
    Focus on the strategic layout of the world's top scientist team in the field of healthcare

    2018-2022

  • Xike Intelligent Xike Medical Technology
    Layout of biological sample library; Landing in the research and development of innovative biological drugs; China Health Management Association Industry Company; AI based primary healthcare; AI sports health; AI mental health

    2023

  • Xike Intelligent Xike Medical Technology
    IND China US Dual Report: Xike AI Medical Model Achieves Davos Forum Science and Technology Innovation Award

    2024

Founding shareholder - Xike Medical Group

Xike Medical Group is a large biotechnology and AI R&D and manufacturing integrated platform company headquartered in Hong Kong. The group includes three major segments:

  • Novo Longevity Technology Co., Ltd

    A globally leading integrated industry platform for the research, development, and transformation of ophthalmic drugs and longevity anti-aging products.

  • Xike Digital Biotechnology Group Co., Ltd

    Integrating Hebecell from the United States and New Leaf Biotech from the United Kingdom to create a world-class product that combines stem cells
    A comprehensive platform for the research and development, transformation, and production of cell drugs using NK cells and Car-t cells, with a current valuation of over 500 million US dollars.

  • Xike International Group

    Based on digital health technology, the group has established two business segments in Hong Kong, China: "Health Digital Twin" and "Xike Smart Selection"
    There are two business segments in mainland China: "Medical and Health Digital Asset Listing" and "Medical and Health Digital Asset and Data Product Trading Space".

Why choose us

Bringing together world-renowned ophthalmologists, the chief scientist leads a team that has been deeply involved in ophthalmic research, clinical practice, and translation for decades;

Corporate culture

  • Our goals and positioning

    The research and development of globally leading ophthalmic drugs and longevity anti-aging products
    Integrated Industry Platform for Conversion

  • our mission

    Promote human health, longevity, and happiness

  • Our vision

    A Thousand Gold and One Promise, World Harmony

  • Our values

    Innovation, Excellence, and Sharing

New Horizon Longevity Technology Co., Limited occupies a high ground in eye health research and clinical practice, laying out technological innovation in the entire diagnosis and treatment chain.
The product includes Herbal Brightening and Aging Eye Care Liquid, Macular Eye Care Liquid, Eye Moisturizing Spray, etc.
Laohua Eye Protection Liquid, a traditional Chinese medicine product under the name of Materia Medica, is the second monomeric product under modern medical technology after artemisinin; Macular eye care solution can alleviate visual impairment caused by macular degeneration; Moisturizing eye spray can prevent eye diseases and relieve visual fatigue.
Some of the company's pipelines have entered the stage of full industrialization and plan to go public in the United States in 2025. After going public, they will use capital market financing to promote the clinical and industrialization of other pipelines.